Apply to the Career Development Program (CDP) Thumbnail Image Read more about Apply to the Career Development Program (CDP)
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer Thumbnail Image Read more about Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Thumbnail Image Read more about Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, in Preclinical Leukemia Models at the European Hematology Association Congress Thumbnail Image Read more about Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, in Preclinical Leukemia Models at the European Hematology Association Congress
Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Thumbnail Image Read more about Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress
Immune-Onc Therapeutics Announces IO-202 Granted Fast Track Designation by FDA for the Treatment of Relapsed or Refractory CMML Thumbnail Image Read more about Immune-Onc Therapeutics Announces IO-202 Granted Fast Track Designation by FDA for the Treatment of Relapsed or Refractory CMML
Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023 Thumbnail Image Read more about Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA Thumbnail Image Read more about Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 EHA Congress Thumbnail Image Read more about Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 EHA Congress
Gilead and Kite Oncology to Showcase Axicabtagene Ciloleucel Advances at ASCO 2023 Thumbnail Image Read more about Gilead and Kite Oncology to Showcase Axicabtagene Ciloleucel Advances at ASCO 2023
